Soligenix Inc (SNGX)
3.76
-0.09
(-2.34%)
USD |
NASDAQ |
Sep 27, 16:00
3.78
+0.02
(+0.53%)
After-Hours: 20:00
Soligenix SG&A Expense (Annual): 4.483M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 4.483M |
December 31, 2022 | 6.693M |
December 31, 2021 | 5.009M |
December 31, 2020 | 4.329M |
December 31, 2019 | 3.481M |
December 31, 2018 | 2.952M |
December 31, 2017 | 3.209M |
December 31, 2016 | 3.429M |
December 31, 2015 | 3.597M |
December 31, 2014 | 3.404M |
December 31, 2013 | 2.765M |
December 31, 2012 | 2.633M |
December 31, 2011 | 2.242M |
December 31, 2010 | 2.201M |
Date | Value |
---|---|
December 31, 2009 | 2.860M |
December 31, 2008 | 2.327M |
December 31, 2007 | 3.542M |
December 31, 2006 | 3.111M |
December 31, 2005 | 2.163M |
December 31, 2004 | 2.321M |
December 31, 2003 | 2.505M |
December 31, 2002 | 2.988M |
December 31, 2001 | 1.974M |
December 31, 2000 | 2.102M |
December 31, 1999 | 3.047M |
December 31, 1998 | 3.50M |
December 31, 1997 | 1.50M |
January 31, 1996 | 0.3172M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
3.481M
Minimum
2019
6.693M
Maximum
2022
4.799M
Average
4.483M
Median
2023
SG&A Expense (Annual) Benchmarks
Tonix Pharmaceuticals Holding Corp | 34.75M |
Lixte Biotechnology Holdings Inc | 4.192M |
Edgewise Therapeutics Inc | 23.45M |
Shuttle Pharmaceuticals Holdings Inc | 2.375M |
NovaBay Pharmaceuticals Inc | 12.83M |